Zhang Chengxiang, Chen Shiyuan
Department of Vascular Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui Province, China.
Wideochir Inne Tech Maloinwazyjne. 2024 Nov 28;19(4):465-469. doi: 10.20452/wiitm.2024.17915. eCollection 2024 Dec 27.
With the advancement of minimally invasive techniques, percutaneous transluminal angioplasty with stenting (PTAS) has emerged as a significant treatment approach for lower limb arteriosclerosis obliterans (ASO).
The aim of this study was to evaluate the clinical efficacy of PTAS in patients with lower limb ASO.
A total of 96 ASO patients admitted to our hospital between January 2021 and December 2022 were included in this study. They were divided into 2 groups according to the treatment method: the observation group (n = 48) received PTAS treatment, while the control group (n = 48) underwent percutaneous transluminal angioplasty (PTA). Treatment efficacy was evaluated 30 dayspostsurgery. Pre- and postoperative measurements included the ankle-brachial index (ABI), claudication distance, and quality of life scores derived from the 36-Item Short Form Health Survey (SF-36).Postoperative complications and the rate of target lesion revascularization (TLR) were also recorded.
In the observation group, 29 patients experienced marked improvement and 17 were effectively treated, yielding the total effectiveness rate of 95.83%, which was higher than in the control group (83.33%; P = 0.045). Both groups showed significant improvement in ABI, claudication distance, and SF-36 scores after treatment, with the observation group presenting significantly better results than the control group. There was no difference in the total incidence of complications between the 2 groups (P = 0.24), however, the TLR occurrence rate was lower in the observation group (P = 0.04).
This study highlights the significant benefits of PTAS in the treatment of ASO, including improved overall effectiveness, enhanced functional indicators, and reduced rate of TLR, thus providing strong evidence for clinicians when selecting treatment methods for patients with lower limb ASO.
随着微创技术的进步，经皮腔内血管成形术联合支架置入术（PTAS）已成为治疗下肢动脉硬化闭塞症（ASO）的重要方法。
本研究旨在评估PTAS治疗下肢ASO患者的临床疗效。
本研究纳入了2021年1月至2022年12月期间我院收治的96例ASO患者。根据治疗方法将他们分为2组：观察组（n = 48）接受PTAS治疗，而对照组（n = 48）接受经皮腔内血管成形术（PTA）。术后30天评估治疗效果。术前和术后测量包括踝臂指数（ABI）、跛行距离以及从36项简短健康调查问卷（SF-36）得出的生活质量评分。还记录了术后并发症和靶病变血运重建率（TLR）。
观察组中，29例患者显著改善，17例有效治疗，总有效率为95.83%，高于对照组（83.33%；P = 0.045）。两组治疗后ABI、跛行距离和SF-36评分均有显著改善，观察组的结果明显优于对照组。两组并发症总发生率无差异（P = 0.24），然而，观察组的TLR发生率较低（P = 0.04）。
本研究强调了PTAS在治疗ASO方面的显著益处，包括提高总体疗效、改善功能指标以及降低TLR发生率，从而为临床医生在为下肢ASO患者选择治疗方法时提供了有力证据。
